Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

At Multiple Sclerosis News Today, stories about the keto diet, myelin repair, and vitamin D topped this year's most-read list ...

England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...

The team, consisting of researchers from University College London (UCL) and Queen Square Analytics, analysed 634 patients ...

Two novel sub-types of multiple sclerosis (MS) have been identified, a discovery potentially paving the way for new treatments. Researchers employed artificial intelligence (AI) to assess brain scans ...

Thousands of people in England with a type of multiple sclerosis (MS) are set to benefit from a new treatment on the NHS.

Using artificial intelligence (AI), researchers looked at brain scans and tested for a blood marker for nerve cell injury and found two new sub-types of the condition. MS affects the brain and spinal ...

Annual out-of-pocket costs for multiple sclerosis (MS) care in the US increased by 125% from 2002 to 2021, primarily driven by newer disease-modifying therapies (DMTs), a new study showed. Researchers ...

MS is currently treated with 'disease-modifying' medicines (e.g. interferon beta, glatiramer acetate, natalizumab, fingolimod, alemtuzumab, teriflunomide, and dimethyl fumarate). These medicines can ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...